{ "kind": "all", "value": "all", "collectionKey": "slides:all:all:all-document-kinds:all-producers:all-orientations", "filters": { "documentKinds": [], "sourceTypes": [], "orientations": [] }, "total": 319975, "page": 9278, "pageSize": 30, "pageCount": 10666, "rows": [ { "docId": "019de514-4d4c-7369-a2bf-f736423e3911", "docSlug": "b1cdb8c0597ad8aabf7d9d24c5430a53", "documentTitle": "Imara | Mergers and Acquisitions Presentation Deck | 45 slides", "authorId": "imara", "authorName": "Enliven Therapeutics / Imara", "documentKindSlug": "press-release", "documentKindLabel": "Press release", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 9, "slideType": "problem_statement", "function": "diagnose_problem", "notes": "The slide uses a split-screen layout to contrast clinical challenges with the specific reasons for treatment switching.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de514-4d4c-7369-a2bf-f736423e3911/9", "deckHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911", "deckAnchorHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911#slide-9", "loopMatches": [], "arcBeatMatches": [ { "to": 20, "from": 9, "beatId": "f1c5daaa-0597-4f81-b694-1845468beefb", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Problem", "beatSlug": "sequoia-pitch-problem", "evidence": "The document identifies a significant need for better treatment options for chronic myeloid leukemia and other cancers.", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de514-4d4c-7369-a2bf-f736423e3911", "docSlug": "b1cdb8c0597ad8aabf7d9d24c5430a53", "documentTitle": "Imara | Mergers and Acquisitions Presentation Deck | 45 slides", "authorId": "imara", "authorName": "Enliven Therapeutics / Imara", "documentKindSlug": "press-release", "documentKindLabel": "Press release", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 10, "slideType": "executive_summary", "function": "size_opportunity", "notes": "Includes a line chart showing treatment duration and a pie chart showing patient outcomes.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de514-4d4c-7369-a2bf-f736423e3911/10", "deckHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911", "deckAnchorHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911#slide-10", "loopMatches": [], "arcBeatMatches": [ { "to": 20, "from": 9, "beatId": "f1c5daaa-0597-4f81-b694-1845468beefb", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Problem", "beatSlug": "sequoia-pitch-problem", "evidence": "The document identifies a significant need for better treatment options for chronic myeloid leukemia and other cancers.", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" }, { "to": 29, "from": 10, "beatId": "d6182004-7274-41e9-b235-3a0a93f6cc05", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents ELVN-001 and ELVN-002 as potential solutions to the problem, with a focus on their clinical focus and target product profiles.", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de514-4d4c-7369-a2bf-f736423e3911", "docSlug": "b1cdb8c0597ad8aabf7d9d24c5430a53", "documentTitle": "Imara | Mergers and Acquisitions Presentation Deck | 45 slides", "authorId": "imara", "authorName": "Enliven Therapeutics / Imara", "documentKindSlug": "press-release", "documentKindLabel": "Press release", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 11, "slideType": "comparison_table", "function": "analyze_data", "notes": "Includes scatter plot for MMR correlation and bar chart for therapeutic index comparison.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de514-4d4c-7369-a2bf-f736423e3911/11", "deckHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911", "deckAnchorHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911#slide-11", "loopMatches": [], "arcBeatMatches": [ { "to": 20, "from": 9, "beatId": "f1c5daaa-0597-4f81-b694-1845468beefb", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Problem", "beatSlug": "sequoia-pitch-problem", "evidence": "The document identifies a significant need for better treatment options for chronic myeloid leukemia and other cancers.", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" }, { "to": 29, "from": 10, "beatId": "d6182004-7274-41e9-b235-3a0a93f6cc05", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents ELVN-001 and ELVN-002 as potential solutions to the problem, with a focus on their clinical focus and target product profiles.", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de514-4d4c-7369-a2bf-f736423e3911", "docSlug": "b1cdb8c0597ad8aabf7d9d24c5430a53", "documentTitle": "Imara | Mergers and Acquisitions Presentation Deck | 45 slides", "authorId": "imara", "authorName": "Enliven Therapeutics / Imara", "documentKindSlug": "press-release", "documentKindLabel": "Press release", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 12, "slideType": "key_messages", "function": "present_solution", "notes": "The slide outlines three strategic pillars (Drive Deeper Responses, Improve Tolerability, Enhance Safety & Convenience) and maps them to specific clinical development programs.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de514-4d4c-7369-a2bf-f736423e3911/12", "deckHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911", "deckAnchorHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911#slide-12", "loopMatches": [], "arcBeatMatches": [ { "to": 20, "from": 9, "beatId": "f1c5daaa-0597-4f81-b694-1845468beefb", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Problem", "beatSlug": "sequoia-pitch-problem", "evidence": "The document identifies a significant need for better treatment options for chronic myeloid leukemia and other cancers.", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" }, { "to": 29, "from": 10, "beatId": "d6182004-7274-41e9-b235-3a0a93f6cc05", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents ELVN-001 and ELVN-002 as potential solutions to the problem, with a focus on their clinical focus and target product profiles.", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" }, { "to": 16, "from": 12, "beatId": "c5896f5c-788f-4fd0-9b6e-5b25251433b2", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Product", "beatSlug": "sequoia-pitch-product", "evidence": "The document presents the key features and benefits of ELVN-001 and ELVN-002, including their clinical focus and target product profiles.", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de514-4d4c-7369-a2bf-f736423e3911", "docSlug": "b1cdb8c0597ad8aabf7d9d24c5430a53", "documentTitle": "Imara | Mergers and Acquisitions Presentation Deck | 45 slides", "authorId": "imara", "authorName": "Enliven Therapeutics / Imara", "documentKindSlug": "press-release", "documentKindLabel": "Press release", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 13, "slideType": "before_after", "function": "frame_problem", "notes": "Uses a before-after-bridge structure to contrast market limitations with product advantages.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de514-4d4c-7369-a2bf-f736423e3911/13", "deckHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911", "deckAnchorHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911#slide-13", "loopMatches": [], "arcBeatMatches": [ { "to": 20, "from": 9, "beatId": "f1c5daaa-0597-4f81-b694-1845468beefb", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Problem", "beatSlug": "sequoia-pitch-problem", "evidence": "The document identifies a significant need for better treatment options for chronic myeloid leukemia and other cancers.", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" }, { "to": 29, "from": 10, "beatId": "d6182004-7274-41e9-b235-3a0a93f6cc05", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents ELVN-001 and ELVN-002 as potential solutions to the problem, with a focus on their clinical focus and target product profiles.", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" }, { "to": 16, "from": 12, "beatId": "c5896f5c-788f-4fd0-9b6e-5b25251433b2", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Product", "beatSlug": "sequoia-pitch-product", "evidence": "The document presents the key features and benefits of ELVN-001 and ELVN-002, including their clinical focus and target product profiles.", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de514-4d4c-7369-a2bf-f736423e3911", "docSlug": "b1cdb8c0597ad8aabf7d9d24c5430a53", "documentTitle": "Imara | Mergers and Acquisitions Presentation Deck | 45 slides", "authorId": "imara", "authorName": "Enliven Therapeutics / Imara", "documentKindSlug": "press-release", "documentKindLabel": "Press release", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 14, "slideType": "market_sizing", "function": "size_opportunity", "notes": "The chart uses a broken axis to represent the significantly larger patient population for HER2 overexpressing cancers compared to mutations.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de514-4d4c-7369-a2bf-f736423e3911/14", "deckHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911", "deckAnchorHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911#slide-14", "loopMatches": [], "arcBeatMatches": [ { "to": 20, "from": 9, "beatId": "f1c5daaa-0597-4f81-b694-1845468beefb", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Problem", "beatSlug": "sequoia-pitch-problem", "evidence": "The document identifies a significant need for better treatment options for chronic myeloid leukemia and other cancers.", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" }, { "to": 29, "from": 10, "beatId": "d6182004-7274-41e9-b235-3a0a93f6cc05", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents ELVN-001 and ELVN-002 as potential solutions to the problem, with a focus on their clinical focus and target product profiles.", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" }, { "to": 15, "from": 14, "beatId": "3e5677d2-ea59-45fb-ac7d-081fc2ce40a4", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Market Size", "beatSlug": "sequoia-pitch-market-size", "evidence": "The document discusses the market size and potential for ELVN-002 in HER2 mutant NSCLC and other HER2-driven cancers.", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" }, { "to": 16, "from": 12, "beatId": "c5896f5c-788f-4fd0-9b6e-5b25251433b2", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Product", "beatSlug": "sequoia-pitch-product", "evidence": "The document presents the key features and benefits of ELVN-001 and ELVN-002, including their clinical focus and target product profiles.", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de514-4d4c-7369-a2bf-f736423e3911", "docSlug": "b1cdb8c0597ad8aabf7d9d24c5430a53", "documentTitle": "Imara | Mergers and Acquisitions Presentation Deck | 45 slides", "authorId": "imara", "authorName": "Enliven Therapeutics / Imara", "documentKindSlug": "press-release", "documentKindLabel": "Press release", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 15, "slideType": "comparison_table", "function": "compare_peers", "notes": "The chart uses a logarithmic scale for selectivity. The right side provides a qualitative critique of competitor molecules.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de514-4d4c-7369-a2bf-f736423e3911/15", "deckHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911", "deckAnchorHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911#slide-15", "loopMatches": [], "arcBeatMatches": [ { "to": 20, "from": 9, "beatId": "f1c5daaa-0597-4f81-b694-1845468beefb", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Problem", "beatSlug": "sequoia-pitch-problem", "evidence": "The document identifies a significant need for better treatment options for chronic myeloid leukemia and other cancers.", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" }, { "to": 29, "from": 10, "beatId": "d6182004-7274-41e9-b235-3a0a93f6cc05", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents ELVN-001 and ELVN-002 as potential solutions to the problem, with a focus on their clinical focus and target product profiles.", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" }, { "to": 15, "from": 14, "beatId": "3e5677d2-ea59-45fb-ac7d-081fc2ce40a4", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Market Size", "beatSlug": "sequoia-pitch-market-size", "evidence": "The document discusses the market size and potential for ELVN-002 in HER2 mutant NSCLC and other HER2-driven cancers.", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" }, { "to": 16, "from": 12, "beatId": "c5896f5c-788f-4fd0-9b6e-5b25251433b2", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Product", "beatSlug": "sequoia-pitch-product", "evidence": "The document presents the key features and benefits of ELVN-001 and ELVN-002, including their clinical focus and target product profiles.", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de514-4d4c-7369-a2bf-f736423e3911", "docSlug": "b1cdb8c0597ad8aabf7d9d24c5430a53", "documentTitle": "Imara | Mergers and Acquisitions Presentation Deck | 45 slides", "authorId": "imara", "authorName": "Enliven Therapeutics / Imara", "documentKindSlug": "press-release", "documentKindLabel": "Press release", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 16, "slideType": "key_messages", "function": "summarize", "notes": "Includes a list of abbreviations at the bottom.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de514-4d4c-7369-a2bf-f736423e3911/16", "deckHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911", "deckAnchorHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911#slide-16", "loopMatches": [], "arcBeatMatches": [ { "to": 20, "from": 9, "beatId": "f1c5daaa-0597-4f81-b694-1845468beefb", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Problem", "beatSlug": "sequoia-pitch-problem", "evidence": "The document identifies a significant need for better treatment options for chronic myeloid leukemia and other cancers.", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" }, { "to": 29, "from": 10, "beatId": "d6182004-7274-41e9-b235-3a0a93f6cc05", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents ELVN-001 and ELVN-002 as potential solutions to the problem, with a focus on their clinical focus and target product profiles.", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" }, { "to": 16, "from": 12, "beatId": "c5896f5c-788f-4fd0-9b6e-5b25251433b2", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Product", "beatSlug": "sequoia-pitch-product", "evidence": "The document presents the key features and benefits of ELVN-001 and ELVN-002, including their clinical focus and target product profiles.", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de514-4d4c-7369-a2bf-f736423e3911", "docSlug": "b1cdb8c0597ad8aabf7d9d24c5430a53", "documentTitle": "Imara | Mergers and Acquisitions Presentation Deck | 45 slides", "authorId": "imara", "authorName": "Enliven Therapeutics / Imara", "documentKindSlug": "press-release", "documentKindLabel": "Press release", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 17, "slideType": "timeline", "function": "plan_implementation", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de514-4d4c-7369-a2bf-f736423e3911/17", "deckHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911", "deckAnchorHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911#slide-17", "loopMatches": [], "arcBeatMatches": [ { "to": 20, "from": 9, "beatId": "f1c5daaa-0597-4f81-b694-1845468beefb", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Problem", "beatSlug": "sequoia-pitch-problem", "evidence": "The document identifies a significant need for better treatment options for chronic myeloid leukemia and other cancers.", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" }, { "to": 29, "from": 10, "beatId": "d6182004-7274-41e9-b235-3a0a93f6cc05", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents ELVN-001 and ELVN-002 as potential solutions to the problem, with a focus on their clinical focus and target product profiles.", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de514-4d4c-7369-a2bf-f736423e3911", "docSlug": "b1cdb8c0597ad8aabf7d9d24c5430a53", "documentTitle": "Imara | Mergers and Acquisitions Presentation Deck | 45 slides", "authorId": "imara", "authorName": "Enliven Therapeutics / Imara", "documentKindSlug": "press-release", "documentKindLabel": "Press release", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 18, "slideType": "cover", "function": "front_matter", "notes": "Includes a stylized chemical structure graphic.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de514-4d4c-7369-a2bf-f736423e3911/18", "deckHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911", "deckAnchorHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911#slide-18", "loopMatches": [], "arcBeatMatches": [ { "to": 20, "from": 9, "beatId": "f1c5daaa-0597-4f81-b694-1845468beefb", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Problem", "beatSlug": "sequoia-pitch-problem", "evidence": "The document identifies a significant need for better treatment options for chronic myeloid leukemia and other cancers.", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" }, { "to": 29, "from": 10, "beatId": "d6182004-7274-41e9-b235-3a0a93f6cc05", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents ELVN-001 and ELVN-002 as potential solutions to the problem, with a focus on their clinical focus and target product profiles.", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de514-4d4c-7369-a2bf-f736423e3911", "docSlug": "b1cdb8c0597ad8aabf7d9d24c5430a53", "documentTitle": "Imara | Mergers and Acquisitions Presentation Deck | 45 slides", "authorId": "imara", "authorName": "Enliven Therapeutics / Imara", "documentKindSlug": "press-release", "documentKindLabel": "Press release", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 19, "slideType": "executive_summary", "function": "establish_context", "notes": "Includes a timeline of key drug approvals and a survival probability chart.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de514-4d4c-7369-a2bf-f736423e3911/19", "deckHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911", "deckAnchorHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911#slide-19", "loopMatches": [], "arcBeatMatches": [ { "to": 20, "from": 9, "beatId": "f1c5daaa-0597-4f81-b694-1845468beefb", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Problem", "beatSlug": "sequoia-pitch-problem", "evidence": "The document identifies a significant need for better treatment options for chronic myeloid leukemia and other cancers.", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" }, { "to": 29, "from": 10, "beatId": "d6182004-7274-41e9-b235-3a0a93f6cc05", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents ELVN-001 and ELVN-002 as potential solutions to the problem, with a focus on their clinical focus and target product profiles.", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de514-4d4c-7369-a2bf-f736423e3911", "docSlug": "b1cdb8c0597ad8aabf7d9d24c5430a53", "documentTitle": "Imara | Mergers and Acquisitions Presentation Deck | 45 slides", "authorId": "imara", "authorName": "Enliven Therapeutics / Imara", "documentKindSlug": "press-release", "documentKindLabel": "Press release", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 20, "slideType": "problem_statement", "function": "diagnose_problem", "notes": "The slide uses a split-screen layout to contrast clinical challenges with the rationale for treatment switching.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de514-4d4c-7369-a2bf-f736423e3911/20", "deckHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911", "deckAnchorHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911#slide-20", "loopMatches": [ { "to": 29, "from": 20, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "cb84aefe-a7ad-46b2-afcc-84f44e849500", "evidence": "The document discusses the limitations and toxicity of current treatments for CML, highlighting the need for better options.", "position": 0, "objective": "What are the consequences of not having better treatment options for CML?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 20, "from": 9, "beatId": "f1c5daaa-0597-4f81-b694-1845468beefb", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Problem", "beatSlug": "sequoia-pitch-problem", "evidence": "The document identifies a significant need for better treatment options for chronic myeloid leukemia and other cancers.", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" }, { "to": 29, "from": 10, "beatId": "d6182004-7274-41e9-b235-3a0a93f6cc05", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents ELVN-001 and ELVN-002 as potential solutions to the problem, with a focus on their clinical focus and target product profiles.", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de514-4d4c-7369-a2bf-f736423e3911", "docSlug": "b1cdb8c0597ad8aabf7d9d24c5430a53", "documentTitle": "Imara | Mergers and Acquisitions Presentation Deck | 45 slides", "authorId": "imara", "authorName": "Enliven Therapeutics / Imara", "documentKindSlug": "press-release", "documentKindLabel": "Press release", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 21, "slideType": "comparison_table", "function": "compare_peers", "notes": "The slide uses a comparative table to frame the problem of current drug limitations, setting up a solution-oriented conclusion.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de514-4d4c-7369-a2bf-f736423e3911/21", "deckHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911", "deckAnchorHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911#slide-21", "loopMatches": [ { "to": 29, "from": 20, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "cb84aefe-a7ad-46b2-afcc-84f44e849500", "evidence": "The document discusses the limitations and toxicity of current treatments for CML, highlighting the need for better options.", "position": 0, "objective": "What are the consequences of not having better treatment options for CML?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 29, "from": 10, "beatId": "d6182004-7274-41e9-b235-3a0a93f6cc05", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents ELVN-001 and ELVN-002 as potential solutions to the problem, with a focus on their clinical focus and target product profiles.", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de514-4d4c-7369-a2bf-f736423e3911", "docSlug": "b1cdb8c0597ad8aabf7d9d24c5430a53", "documentTitle": "Imara | Mergers and Acquisitions Presentation Deck | 45 slides", "authorId": "imara", "authorName": "Enliven Therapeutics / Imara", "documentKindSlug": "press-release", "documentKindLabel": "Press release", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 22, "slideType": "key_takeaways", "function": "summarize", "notes": "Includes clinical trial data and resistance mutation analysis.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de514-4d4c-7369-a2bf-f736423e3911/22", "deckHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911", "deckAnchorHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911#slide-22", "loopMatches": [ { "to": 29, "from": 20, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "cb84aefe-a7ad-46b2-afcc-84f44e849500", "evidence": "The document discusses the limitations and toxicity of current treatments for CML, highlighting the need for better options.", "position": 0, "objective": "What are the consequences of not having better treatment options for CML?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 29, "from": 10, "beatId": "d6182004-7274-41e9-b235-3a0a93f6cc05", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents ELVN-001 and ELVN-002 as potential solutions to the problem, with a focus on their clinical focus and target product profiles.", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de514-4d4c-7369-a2bf-f736423e3911", "docSlug": "b1cdb8c0597ad8aabf7d9d24c5430a53", "documentTitle": "Imara | Mergers and Acquisitions Presentation Deck | 45 slides", "authorId": "imara", "authorName": "Enliven Therapeutics / Imara", "documentKindSlug": "press-release", "documentKindLabel": "Press release", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 23, "slideType": "executive_summary", "function": "summarize", "notes": "The slide uses a split-screen layout to contrast current market realities with the company's vision, supported by a survival curve and a patient outcome pie chart.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de514-4d4c-7369-a2bf-f736423e3911/23", "deckHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911", "deckAnchorHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911#slide-23", "loopMatches": [ { "to": 29, "from": 20, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "cb84aefe-a7ad-46b2-afcc-84f44e849500", "evidence": "The document discusses the limitations and toxicity of current treatments for CML, highlighting the need for better options.", "position": 0, "objective": "What are the consequences of not having better treatment options for CML?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 29, "from": 10, "beatId": "d6182004-7274-41e9-b235-3a0a93f6cc05", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents ELVN-001 and ELVN-002 as potential solutions to the problem, with a focus on their clinical focus and target product profiles.", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de514-4d4c-7369-a2bf-f736423e3911", "docSlug": "b1cdb8c0597ad8aabf7d9d24c5430a53", "documentTitle": "Imara | Mergers and Acquisitions Presentation Deck | 45 slides", "authorId": "imara", "authorName": "Enliven Therapeutics / Imara", "documentKindSlug": "press-release", "documentKindLabel": "Press release", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 24, "slideType": "comparison_table", "function": "diagnose_problem", "notes": "The slide uses a custom table structure to show competitive positioning of ELVN-001 against existing TKI generations.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de514-4d4c-7369-a2bf-f736423e3911/24", "deckHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911", "deckAnchorHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911#slide-24", "loopMatches": [ { "to": 29, "from": 20, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "cb84aefe-a7ad-46b2-afcc-84f44e849500", "evidence": "The document discusses the limitations and toxicity of current treatments for CML, highlighting the need for better options.", "position": 0, "objective": "What are the consequences of not having better treatment options for CML?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 29, "from": 10, "beatId": "d6182004-7274-41e9-b235-3a0a93f6cc05", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents ELVN-001 and ELVN-002 as potential solutions to the problem, with a focus on their clinical focus and target product profiles.", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de514-4d4c-7369-a2bf-f736423e3911", "docSlug": "b1cdb8c0597ad8aabf7d9d24c5430a53", "documentTitle": "Imara | Mergers and Acquisitions Presentation Deck | 45 slides", "authorId": "imara", "authorName": "Enliven Therapeutics / Imara", "documentKindSlug": "press-release", "documentKindLabel": "Press release", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 25, "slideType": "key_messages", "function": "present_solution", "notes": "The slide outlines the strategic positioning of a drug candidate (ELVN-001) by contrasting its desired profile against current standards of care.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de514-4d4c-7369-a2bf-f736423e3911/25", "deckHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911", "deckAnchorHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911#slide-25", "loopMatches": [ { "to": 29, "from": 20, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "cb84aefe-a7ad-46b2-afcc-84f44e849500", "evidence": "The document discusses the limitations and toxicity of current treatments for CML, highlighting the need for better options.", "position": 0, "objective": "What are the consequences of not having better treatment options for CML?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 29, "from": 10, "beatId": "d6182004-7274-41e9-b235-3a0a93f6cc05", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents ELVN-001 and ELVN-002 as potential solutions to the problem, with a focus on their clinical focus and target product profiles.", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de514-4d4c-7369-a2bf-f736423e3911", "docSlug": "b1cdb8c0597ad8aabf7d9d24c5430a53", "documentTitle": "Imara | Mergers and Acquisitions Presentation Deck | 45 slides", "authorId": "imara", "authorName": "Enliven Therapeutics / Imara", "documentKindSlug": "press-release", "documentKindLabel": "Press release", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 26, "slideType": "key_messages", "function": "present_framework", "notes": "Includes structural biology diagrams of BCR-ABL protein domains and a table comparing binding conformations.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de514-4d4c-7369-a2bf-f736423e3911/26", "deckHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911", "deckAnchorHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911#slide-26", "loopMatches": [ { "to": 29, "from": 20, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "cb84aefe-a7ad-46b2-afcc-84f44e849500", "evidence": "The document discusses the limitations and toxicity of current treatments for CML, highlighting the need for better options.", "position": 0, "objective": "What are the consequences of not having better treatment options for CML?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 29, "from": 10, "beatId": "d6182004-7274-41e9-b235-3a0a93f6cc05", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents ELVN-001 and ELVN-002 as potential solutions to the problem, with a focus on their clinical focus and target product profiles.", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de514-4d4c-7369-a2bf-f736423e3911", "docSlug": "b1cdb8c0597ad8aabf7d9d24c5430a53", "documentTitle": "Imara | Mergers and Acquisitions Presentation Deck | 45 slides", "authorId": "imara", "authorName": "Enliven Therapeutics / Imara", "documentKindSlug": "press-release", "documentKindLabel": "Press release", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 27, "slideType": "comparison_table", "function": "compare_peers", "notes": "The table highlights key differentiators such as lower BCRP substrate status and improved plasma protein binding for ELVN-001.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de514-4d4c-7369-a2bf-f736423e3911/27", "deckHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911", "deckAnchorHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911#slide-27", "loopMatches": [ { "to": 29, "from": 20, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "cb84aefe-a7ad-46b2-afcc-84f44e849500", "evidence": "The document discusses the limitations and toxicity of current treatments for CML, highlighting the need for better options.", "position": 0, "objective": "What are the consequences of not having better treatment options for CML?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 29, "from": 10, "beatId": "d6182004-7274-41e9-b235-3a0a93f6cc05", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents ELVN-001 and ELVN-002 as potential solutions to the problem, with a focus on their clinical focus and target product profiles.", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de514-4d4c-7369-a2bf-f736423e3911", "docSlug": "b1cdb8c0597ad8aabf7d9d24c5430a53", "documentTitle": "Imara | Mergers and Acquisitions Presentation Deck | 45 slides", "authorId": "imara", "authorName": "Enliven Therapeutics / Imara", "documentKindSlug": "press-release", "documentKindLabel": "Press release", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 28, "slideType": "comparison_table", "function": "compare_peers", "notes": "Includes both a competitive cellular phosphorylation table and a specific kinase selectivity table for ELVN-001.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de514-4d4c-7369-a2bf-f736423e3911/28", "deckHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911", "deckAnchorHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911#slide-28", "loopMatches": [ { "to": 29, "from": 20, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "cb84aefe-a7ad-46b2-afcc-84f44e849500", "evidence": "The document discusses the limitations and toxicity of current treatments for CML, highlighting the need for better options.", "position": 0, "objective": "What are the consequences of not having better treatment options for CML?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 29, "from": 10, "beatId": "d6182004-7274-41e9-b235-3a0a93f6cc05", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents ELVN-001 and ELVN-002 as potential solutions to the problem, with a focus on their clinical focus and target product profiles.", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de514-4d4c-7369-a2bf-f736423e3911", "docSlug": "b1cdb8c0597ad8aabf7d9d24c5430a53", "documentTitle": "Imara | Mergers and Acquisitions Presentation Deck | 45 slides", "authorId": "imara", "authorName": "Enliven Therapeutics / Imara", "documentKindSlug": "press-release", "documentKindLabel": "Press release", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 29, "slideType": "comparison_table", "function": "compare_peers", "notes": "The slide uses a scatter plot for efficacy correlation and a bar chart for safety margin comparison.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de514-4d4c-7369-a2bf-f736423e3911/29", "deckHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911", "deckAnchorHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911#slide-29", "loopMatches": [ { "to": 29, "from": 20, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "cb84aefe-a7ad-46b2-afcc-84f44e849500", "evidence": "The document discusses the limitations and toxicity of current treatments for CML, highlighting the need for better options.", "position": 0, "objective": "What are the consequences of not having better treatment options for CML?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 29, "from": 10, "beatId": "d6182004-7274-41e9-b235-3a0a93f6cc05", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents ELVN-001 and ELVN-002 as potential solutions to the problem, with a focus on their clinical focus and target product profiles.", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de514-4d4c-7369-a2bf-f736423e3911", "docSlug": "b1cdb8c0597ad8aabf7d9d24c5430a53", "documentTitle": "Imara | Mergers and Acquisitions Presentation Deck | 45 slides", "authorId": "imara", "authorName": "Enliven Therapeutics / Imara", "documentKindSlug": "press-release", "documentKindLabel": "Press release", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 30, "slideType": "roadmap", "function": "plan_implementation", "notes": "The slide uses a process-oriented layout to show the progression of clinical trials.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de514-4d4c-7369-a2bf-f736423e3911/30", "deckHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911", "deckAnchorHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911#slide-30", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de514-4d4c-7369-a2bf-f736423e3911", "docSlug": "b1cdb8c0597ad8aabf7d9d24c5430a53", "documentTitle": "Imara | Mergers and Acquisitions Presentation Deck | 45 slides", "authorId": "imara", "authorName": "Enliven Therapeutics / Imara", "documentKindSlug": "press-release", "documentKindLabel": "Press release", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 31, "slideType": "section_divider", "function": "frame_situation", "notes": "Features a stylized chemical structure graphic.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de514-4d4c-7369-a2bf-f736423e3911/31", "deckHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911", "deckAnchorHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911#slide-31", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de514-4d4c-7369-a2bf-f736423e3911", "docSlug": "b1cdb8c0597ad8aabf7d9d24c5430a53", "documentTitle": "Imara | Mergers and Acquisitions Presentation Deck | 45 slides", "authorId": "imara", "authorName": "Enliven Therapeutics / Imara", "documentKindSlug": "press-release", "documentKindLabel": "Press release", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 32, "slideType": "before_after", "function": "frame_problem", "notes": "Uses a before-after framing to contrast market limitations with product solution.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de514-4d4c-7369-a2bf-f736423e3911/32", "deckHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911", "deckAnchorHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911#slide-32", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de514-4d4c-7369-a2bf-f736423e3911", "docSlug": "b1cdb8c0597ad8aabf7d9d24c5430a53", "documentTitle": "Imara | Mergers and Acquisitions Presentation Deck | 45 slides", "authorId": "imara", "authorName": "Enliven Therapeutics / Imara", "documentKindSlug": "press-release", "documentKindLabel": "Press release", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 33, "slideType": "market_sizing", "function": "size_opportunity", "notes": "The chart uses a broken axis to represent the significantly larger patient population for HER2 overexpressing cancers compared to the initial focus areas.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de514-4d4c-7369-a2bf-f736423e3911/33", "deckHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911", "deckAnchorHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911#slide-33", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de514-4d4c-7369-a2bf-f736423e3911", "docSlug": "b1cdb8c0597ad8aabf7d9d24c5430a53", "documentTitle": "Imara | Mergers and Acquisitions Presentation Deck | 45 slides", "authorId": "imara", "authorName": "Enliven Therapeutics / Imara", "documentKindSlug": "press-release", "documentKindLabel": "Press release", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 34, "slideType": "comparison_table", "function": "compare_peers", "notes": "The slide contrasts established therapies with investigational ones, emphasizing the lack of selective TKIs and the resulting toxicity issues.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de514-4d4c-7369-a2bf-f736423e3911/34", "deckHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911", "deckAnchorHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911#slide-34", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de514-4d4c-7369-a2bf-f736423e3911", "docSlug": "b1cdb8c0597ad8aabf7d9d24c5430a53", "documentTitle": "Imara | Mergers and Acquisitions Presentation Deck | 45 slides", "authorId": "imara", "authorName": "Enliven Therapeutics / Imara", "documentKindSlug": "press-release", "documentKindLabel": "Press release", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 35, "slideType": "comparison_table", "function": "compare_peers", "notes": "The slide highlights a gap in the market for a selective, irreversible TKI for brain metastases.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de514-4d4c-7369-a2bf-f736423e3911/35", "deckHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911", "deckAnchorHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911#slide-35", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de514-4d4c-7369-a2bf-f736423e3911", "docSlug": "b1cdb8c0597ad8aabf7d9d24c5430a53", "documentTitle": "Imara | Mergers and Acquisitions Presentation Deck | 45 slides", "authorId": "imara", "authorName": "Enliven Therapeutics / Imara", "documentKindSlug": "press-release", "documentKindLabel": "Press release", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 36, "slideType": "key_messages", "function": "summarize", "notes": "Includes a list of abbreviations at the bottom.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de514-4d4c-7369-a2bf-f736423e3911/36", "deckHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911", "deckAnchorHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911#slide-36", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de514-4d4c-7369-a2bf-f736423e3911", "docSlug": "b1cdb8c0597ad8aabf7d9d24c5430a53", "documentTitle": "Imara | Mergers and Acquisitions Presentation Deck | 45 slides", "authorId": "imara", "authorName": "Enliven Therapeutics / Imara", "documentKindSlug": "press-release", "documentKindLabel": "Press release", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 37, "slideType": "comparison_table", "function": "compare_peers", "notes": "The table uses a heatmap-style color coding (green for favorable, red for unfavorable) to visualize potency differences.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de514-4d4c-7369-a2bf-f736423e3911/37", "deckHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911", "deckAnchorHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911#slide-37", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de514-4d4c-7369-a2bf-f736423e3911", "docSlug": "b1cdb8c0597ad8aabf7d9d24c5430a53", "documentTitle": "Imara | Mergers and Acquisitions Presentation Deck | 45 slides", "authorId": "imara", "authorName": "Enliven Therapeutics / Imara", "documentKindSlug": "press-release", "documentKindLabel": "Press release", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 38, "slideType": "comparison_table", "function": "compare_peers", "notes": "The table highlights ELVN-002's superior selectivity (sparing EGFR) and better pharmacokinetic properties compared to competitors.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de514-4d4c-7369-a2bf-f736423e3911/38", "deckHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911", "deckAnchorHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911#slide-38", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true } ] }